What is CAMP's market cap?

CAMP4 Therapeutics Corporation (CAMP) is a listed stock with a live quote. The latest market cap on this page is $233M.

Where is CAMP4 Therapeutics Corporation headquartered?

CAMP4 Therapeutics Corporation is headquartered in Cambridge, MA.

How do I get CAMP news from the API?

Call GET /v1/news?tickers=CAMP. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does CAMP news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CAMP, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the CAMP price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email sales@marketnewsapi.com.

CAMP · NASDAQ

CAMP4 Therapeutics Corporation

$3.72 -0.02 (-0.53%)

Company overview

CAMP4 Therapeutics Corp. operates as a biotechnology company engaged in discovering treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $233M
Employees: 55
Headquarters: Cambridge, MA
Website: camp4tx.com
CEO: Joshua Mandel-Brehm
Listed: October 11, 2024
P/E: -1.64
Dividend yield: 0.00%

Company financials

Revenue: $3.9M
Gross profit: $3M
Operating income: -$52M
EBITDA: -$52.2M
Net income: -$86.3M
EPS: -$2.27
Total assets: $105M
Total debt: $2.1M
Gross margin: 76.21%
Net margin: -2,193.72%
Earnings yield: -61.02%

Revenue segmentation

By product (FY 2022)

By region (FY 2022)

Showing FY 2022

Price chart

CAMP 1D NASDAQ O4.01H4.01L3.73C3.74-0.09 (-2.35%)Vol126.77K

News

Ticker	Type	Headline	Source	Published
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights	GlobeNewswire	Nov 5, 4:06:47 PM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release	Zacks Investment Research	Oct 29, 11:06:48 AM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union	GlobeNewswire	Oct 27, 8:00:00 AM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference	GlobeNewswire	Oct 14, 8:00:00 AM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript	Seeking Alpha	Sep 28, 7:33:21 PM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002	MarketBeat	Sep 28, 3:02:37 PM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder	GlobeNewswire	Sep 10, 7:33:22 AM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026	GlobeNewswire	Sep 8, 4:05:00 PM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 to Participate in Upcoming Investor Conferences	GlobeNewswire	Sep 1, 4:05:00 PM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec	TheNewswire	Aug 31, 5:05:00 PM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec	TheNewswire	Aug 18, 8:05:00 AM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates	Zacks Investment Research	Aug 13, 7:51:27 PM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights	GlobeNewswire	Aug 13, 4:05:00 PM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	CAMP4 advances rare disease treatment for SYNGAP1 into human trials	CNBC	Aug 6, 2:52:12 PM ET
CAMPCAMP4 Therapeutics Corporation	Press release	SIX FLAGS GREAT AMERICA ANNOUNCES CAMP TIMBER TRAIL, AN ALL-NEW FAMILY ADVENTURE FOR 2027	PRNewsWire	Aug 6, 9:05:00 AM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement	GlobeNewswire	Aug 4, 7:00:00 AM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder	GlobeNewswire	Jul 27, 7:00:00 AM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GlobeNewswire	Jul 17, 4:05:00 PM ET
CAMPCAMP4 Therapeutics Corporation	Press release	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GlobeNewswire	Jul 17, 4:05:00 PM ET
CAMPCAMP4 Therapeutics Corporation	Stock news	New Strong Sell Stocks for July 16th	Zacks Investment Research	Jul 16, 5:35:14 AM ET

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.